1. Scrip
  2. >>Archive

Steve Pakola leaves Thrombogenics for Amakem

 
• By Gemma Sharman

Dr Steve Pakola has taken the role of CMO at Amakem, having previously served as CMO of Thrombogenics, where he played a pivotal role in the development of the company's lead product, ocriplasmin, which is under review in Europe as a treatment for symptomatic vitreomacular adhesion and has been filed for priority review in the US. Dr Pakola has been replaced at Thrombogenics by Dr Aniz Girach, who joined the company a year and a half ago as global head of clinical ophthalmology and was previously vice-president of international clinical development of ophthalmology at Alcon.

Dr Steve Pakola has taken the role of CMO at Amakem, having previously served as CMO of Thrombogenics, where he played a pivotal role in the development of the company's lead product, ocriplasmin, which is under review in Europe as a treatment for symptomatic vitreomacular adhesion and has been filed for priority review in the US. Dr Pakola has been replaced at Thrombogenics by Dr Aniz Girach, who joined the company a year and a half ago as global head of clinical ophthalmology and was previously vice-president of international clinical development of ophthalmology at Alcon.

Amakem has also appointed Dr George Lasezkay to its board of directors. Dr Lasezkay was previously corporate vice-president of corporate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.